[ad_1]
So far, the Bangladesh Department of Drug Administration has given eight drug manufacturers permission to produce the drug. The companies are Beximco, Incepta, Square, SKF, Beacon, Health Care, Popular, and Opsonin.
Ruhul Amin, director of the Department of Drug Administration, said SKF, Beximco and Incepta Pharmaceuticals have started production of the remedy.
He told bdnews24.com on Friday that SKF had already produced two batches of the drug. On Sunday they will send drug samples.
“After we send the sample, we will test here. If the results are satisfactory, they will be given marketing authorization. Once they get the authorization certificate, they can market. “
He said the rule would apply only to the approval of corrective medications produced by all companies. The drug is expected to be released later this month.
Ruhul Amin said the companies will deliver the locally made medicine to the government. If it has to be delivered to a private hospital, pharmaceutical companies can do so with the permission of the Department of Health.
According to officials from the Department of Drug Administration and the manufacturing company, the price of each dose of Remediciv will be around Rs 5,000 per dose. An adult patient has to inject 10 to 12 doses of the drug as recommended by the doctor.
SKF Pharmaceuticals Limited, Director of Marketing and Sales. Mohammad Mujahidul Islam told bdnews24.com on Friday that the drug would be sent to the quality control laboratory of the Department of Drug Administration. The marketing certificate will be available after passing the standard.
“We are the first company in Bangladesh to complete all stages of production of this medicine. Hopefully, within the next two business days, we will be able to complete these jobs and begin drug distribution activities very soon. ”
Covid-19: US Remedies. USA For emergencies
Rabbur Reza, director of operations for Beximco Pharmaceuticals, said they have also started production of the remedy.
Rabbur Reza declined to comment on the stage of production of the drug.
However, the Beximco official told bdnews24.com: “We hope to complete the process and market the drug this month. We will initially supply it in Bangladesh. Bangladesh is our priority. We will see how much medicine is needed here.”
He said they would give the drugs to the government through the Department of Drug Administration. With government permission, it will be provided for the treatment of patients with Kovid-19 in private hospitals.
When asked about the price of the drug, Rabbur Reza said, “This price will not affect the patient.” They will try to further reduce the price.
“It just came to our attention then. Before marketing each drug, a price must be set according to the rules of the Department of Drug Administration. But it won’t apply to this drug.
“When we give it to the government, we will give it for free or we will sell it at a reasonable price. But at a stage when the government is no longer needed, we will deliver the medicine to the market. I will still try to administer the medicine at the lowest price in the world “.
Abdul Muktadir, president and managing director of Incepta Pharmaceuticals, told bdnews24.com: “We are experimenting here. If at any time it is not correct, then it must be done again. For this reason, the time cannot be specified. We have started production Inshallah, I can give it to you real quick.
Coronavirus drugs called ‘propaganda’
The drug was developed by the American company Gilead Sciences. Among other things, the United States Food and Drug Administration (FDA) last week approved the use of the drug in cases of emergency treatment with coronavirus.
Remdesiv was created to treat Ebola. On April 29, the US government. USA He announced that the duration of symptoms of Covid-19 patients had decreased from 15 days to 11 days with the experimental application of remedicivir in the hospital.
Experts praised the results as “great,” but said the drug would not be a “magic bullet” in the fight against Kovid-19.
The drug, administered by the National Institute of Allergy and Infectious Diseases (NIAID) in the United States, was administered to 1,083 patients. However, the effect of this medicine to prevent death is still unclear.
The mortality rate among the patients found with remediation was 6 percent and 11 percent among others. Scientists have not been able to confirm whether drugs have played a role in making this difference.
In the pharmaceutical industry, Bangladesh, as a least developed country, can legally manufacture the drug in accordance with the provisions of the World Trade Organization (WTO) intellectual property rights agreement or the Aspects of Intellectual Property Rights related to the Trade (TRIPS).
The virus has been found in 13,134 people in Bangladesh since the coronavirus was identified on March 8. It killed 206 people. However, the number of victims gradually increases, 609 people have been infected in the last 24 hours.
[ad_2]
